Table 1. Demographic and clinical patient characteristics.
| Ulcerative colitis (n = 30) | Crohn’s disease (n = 52) | |
| Age, median (range), years | 47 (20 – 62) | 42 (19 – 72) |
| Male, n (%) | 17 (56.7) | 23 (44.2) |
| Disease duration, mean ± SD (range), years | 10.1 ± 7.4 | 12.4 ± 11.6 |
| Disease extension, n (%) | ||
| Proctitis | 1 (3.3) | |
| Pancolitis | 17 (56.7) | |
| Left sided | 12 (40) | |
| Terminal ileum | 14 (26.9) | |
| Colonic | 10 (19.2) | |
| Ileocolitis | 28 (53.9) | |
| Current medication, n (%) | ||
| None | 0 (0) | 8 (15.4) |
| Mesalazine | 10 (33.3) | 2 (3.8) |
| Azathioprine/methotrexate | 1 (3.3) | 5 (9.6) |
| Anti-TNF | 12 (40) | 24 (46.2) |
| Vedolizumab | 6 (20) | 2 (3.8) |
| Ustekinumab | 4 (7.7) | |
| Combination therapy | 1 (3.3) | 3 (5.8) |
| Steroids | 0 (0) | 4 (7.7) |
| Clinical activity scores, n (%) | ||
| Mayo score | ||
| ≤ 5 | 21 | |
| ≥ 5 | 9 | |
| CDAI | ||
| ≤ 150 | 32 | |
| ≥ 150 | 20 | |
| Endoscopic scores, mean ± SD | ||
| Mayo score | 1.8 ± 1.3 | |
| SES-CD | 8.4 ± 10.9 | |
| Laboratory markers, mean ± SD | ||
| C-reactive protein (mg/L) | 7 ± 7.8 | 9.4 ± 13.5 |